[1] Siegel RL, Miller KD, Jemal A.  Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.   doi: 10.3322/caac.21590
[2] Capitanio U, Montorsi F.  Renal cancer[J]. Lancet, 2016, 387(10021): 894-906.   doi: 10.1016/S0140-6736(15)00046-X
[3] Posadas EM, Limvorasak S, Figlin RA.  Targeted therapies for renal cell carcinoma[J]. Nat Rev Nephrol, 2017, 13(8): 496-511.   doi: 10.1038/nrneph.2017.82
[4] 董培, 刘洋, 张志凌, 等.  靶向治疗时代转移性肾癌多学科综合治疗的单中心经验总结[J]. 中华泌尿外科杂志, 2020, 41(1): 1-7.   doi: 10.3760/cma.j.issn.1000-6702.2020.01.001
Dong P, Liu Y, Zhang ZL, et al.  Disciplinary management for metastatic renal cell carcinoma in the ear of targeted therapy: a single center exp[J]. Chin J Urol, 2020, 41(1): 1-7.   doi: 10.3760/cma.j.issn.1000-6702.2020.01.001
[5] 邹俊遐, 陈科.  缺氧诱导因子(HIFs)在肾癌发生中的作用及其分子机制[J]. 遗传, 2018, 40(5): 341-356.   doi: 10.16288/j.yczz.17-406
Zou JX, Chen K.  Roles and molecular mechanisms of hypoxia-inducible factors in renal cell carcinoma[J]. Hereditas, 2018, 40(5): 341-356.   doi: 10.16288/j.yczz.17-406
[6] Choueiri TK, Hessel C, Halabi S, et al.  Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update[J]. Eur J Cancer, 2018, 94: 115-125.   doi: 10.1016/j.ejca.2018.02.012
[7] Ruiz-Morales JM, Swierkowski M, Wells JC, et al.  First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium[J]. Eur J Cancer, 2016, 65: 102-108.   doi: 10.1016/j.ejca.2016.06.016
[8] Therasse P, Arbuck SG, Eisenhauer EA, et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.   doi: 10.1093/jnci/92.3.205
[9] van Persijn van Meerten EL, Gelderblom H, Bloem JL.  RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline[J]. Eur Radiol, 2010, 20(6): 1456-1467.   doi: 10.1007/s00330-009-1685-y
[10]

Ueno D, Yao M, Tateishi U, et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course[J/OL]. BMC Cancer, 2012, 12: 162[2019-03-10]. https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-162. DOI: 10.1186/1471-2407-12-162.
[11] Smith AD, Shah SN, Rini BI, et al.  Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy[J]. AJR Am J Roentgenol, 2010, 194(6): 1470-1478.   doi: 10.2214/AJR.09.3456
[12] Flaherty KT.  Sorafenib in Renal Cell Carcinoma[J]. Clin Cancer Res, 2007, 13(2Suppl): 747s-752s.   doi: 10.1158/1078-0432.CCR-06-2063
[13] Rixe O, Bukowski RM, Michaelson MD, et al.  Axitinib treatment in patients with cytokine-refractory metastatic krenal-cell cancer: a phase Ⅱ study[J]. Lancet Oncol, 2007, 8(11): 975-984.   doi: 10.1016/s1470-2045(07)70285-1
[14] van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, et al.  Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response[J]. Clin Cancer Res, 2008, 14(8): 2431-2436.   doi: 10.1158/1078-0432.CCR-07-4089
[15]

王琳. 靶向时代肿瘤疗效评价标准的探索 [J].中国肿瘤临床, 2015, 42(6): 366−370. DOI: 10.3969/j.issn.1000−8179.20142149.

Wang L. Exploration of tumor response evaluation criteria in the era of tar-geted therapy[J]. Chin J Clin Oncol, 2015, 42(6): 366−370. DOI: 10.3969/j.issn.1000−8179.20142149.
[16] Choi H, Charnsangavej C, Faria SC, et al.  Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria[J]. J Clin Oncol, 2007, 25(13): 1753-1759.   doi: 10.1200/JCO.2006.07.3049
[17] Schmidt N, Hess V, Zumbrunn T, et al.  Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies[J]. Eur Radiol, 2013, 23(3): 632-639.   doi: 10.1007/s00330-012-2640-x
[18] van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, et al.  Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib[J]. Br J Cancer, 2010, 102(5): 803-809.   doi: 10.1038/sj.bjc.6605567
[19] 张百红, 岳红云.  实体瘤疗效评价标准简介[J]. 国际肿瘤学杂志, 2016, 43(11): 845-847.   doi: 10.3760/cma.j.issn.1673-422X.2016.11.011
Zhang BH, Yue HY.  Brief introduction of response evaluation criteria in solid tumors[J]. J Int Oncol, 2016, 43(11): 845-847.   doi: 10.3760/cma.j.issn.1673-422X.2016.11.011
[20] Revheim ME, Winge-Main AK, Hagen G, et al.  Combined Positron Emission Tomography/Computed Tomography in Sunitinib Therapy Assessment of Patients with Metastatic Renal Cell Carcinoma[J]. Clin Oncol (R Coll Radiol), 2011, 23(5): 339-343.   doi: 10.1016/j.clon.2010.11.006
[21]

Lin J, Xie GZ, Liao GX, et al. Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis[J/OL]. Oncotarget, 2017, 8(20): 33884−33896[2019-03-10]. https://www.oncotarget.com/article/13934/text/. DOI: 10.18632/oncotarget.13934.
[22] Ravina M, Saboury B, Chauhan MS, et al.  Utility of 18F-FDG PET/CT in Pre-Surgical Risk Stratification of Patients with Breast Cancer[J]. Hell J Nucl Med, 2019, 22(3): 165-171.   doi: 10.1967/s002449911051
[23]

van Uden DJP, Prins MW, Siesling S, et al. [18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review[J/OL]. Crit Rev Oncol Hematol, 2020, 151: 102943[2019-03-10]. http://doi.org/10.1016/j.critrevonc.2020.102943. DOI: 10.1016/j.critrevonc.2020.102943
[24] Soydal C, Koksoy EB, Yasar A, et al.  Prognostic Importance of Bone Marrow Uptake on Baseline 18F-FDG Positron Emission Tomography in Diffuse Large B Cell Lymphoma[J]. Cancer Biother Radiopharm, 2016, 31(10): 361-365.   doi: 10.1089/cbr.2016.2132
[25] Ding QY, Cheng X, Yang L, et al.  PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST)[J]. J Thorac Dis, 2014, 6(6): 677-683.   doi: 10.3978/j.issn.2072-1439.2014.05.10
[26]

van Weehaeghe D, Gheysens O, Vandecaveye V, et al. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F-FDG-PET/CT[J/OL]. BMC Cancer, 2018, 18: 253[2019-03-10]. https://link.springer.com/article/10.1186/s12885-018-4154-7. DOI: 10.1186/s12885-018-4154-7.
[27]

Nakaigawa N, Kondo K, Tateishi U, et al. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma[J/OL]. BMC Cancer, 2016, 16: 67[2019-03-10]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2097-4. DOI: 10.1186/s12885-016-2097-4.
[28] Minamimoto R, Nakaigawa N, Tateishi U, et al.  Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT[J]. Clin Nucl Med, 2010, 35(12): 918-923.   doi: 10.1097/rlu.0b013e3181f9ddd9
[29] Vercellino L, Bousquet G, Baillet G, et al.  18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study[J]. Cancer Biother Radiopharm, 2009, 24(1): 137-144.   doi: 10.1089/cbr.2008.0527
[30]

Nakaigawa N, Kondo K, Ueno D, et al. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy[J/OL]. BMC Cancer, 2017, 17(1): 39[2019-03-10]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885−016−3044−0. DOI: 10.1186/s12885-016-3044-0.
[31] Ito H, Kondo K, Kawahara T, et al.  One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival[J]. Cancer Chemother Pharmacol, 2017, 79(5): 855-861.   doi: 10.1007/s00280-017-3275-z
[32] Nakaigawa N, Kondo K, Kaneta T, et al.  FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma[J]. Cancer Chemother Pharmacol, 2018, 81(4): 739-744.   doi: 10.1007/s00280-018-3542-7
[33]

Polverari G, Ceci F, Bertaglia V, et al. 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival[J/OL]. Cancers, 2020, 12(5): 1163[2019-03-10]. https://www.mdpi.com/2072−6694/12/5/1163. DOI: 10.3390/cancers12051163.
[34] Moskowitz AJ, Schöder H, Gavane S, et al.  Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma[J]. Blood, 2017, 130(20): 2196-2203.   doi: 10.1182/blood-2017-06-788877
[35] Yoon HJ, Paeng JC, Kwak C, et al.  Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy[J]. Ann Nucl Med, 2013, 27(8): 748-755.   doi: 10.1007/s12149-013-0742-4
[36] Hwang SH, Cho A, Yun MJ, et al.  Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents[J]. Clin Nucl Med, 2017, 42(5): e235-e241.   doi: 10.1097/RLU.0000000000001612
[37] 胡裕效, 朱虹.  PET显像在原发性肾细胞癌中的研究进展[J]. 肿瘤学杂志, 2008, 14(10): 852-855.
Hu YX, Zhu H.  Progress in PET Imaging in Renal Cell Carcinoma[J]. J Oncol, 2008, 14(10): 852-855.
[38] 孟晓云, 陈跃.  肿瘤葡萄糖转运蛋白与脱氧葡萄糖显像剂摄取研究[J]. 实用放射学杂志, 2007, 23(4): 542-545.   doi: 10.3969/j.issn.1002-1671.2007.04.036
Meng XY, Chen Y.  Study on the Tumor GIut and the Uptake of DG Imaging Agent[J]. J Pract Radiol, 2007, 23(4): 542-545.   doi: 10.3969/j.issn.1002-1671.2007.04.036
[39] 宋建华, 赵晋华, 陈香, 等.  18F-FDG PET/CT对肾脏肿瘤的诊断价值[J]. 中华核医学与分子影像杂志, 2013, 33(3): 184-187.   doi: 10.3760/cma.j.issn.2095-2848.2013.03.007
Song JH, Zhao JH, Chen X, et al.  The value of diagnosing kidney neoplasms with 18F-FDG PET/CT[J]. Chin J Nucl Med Mol Imaging, 2013, 33(3): 184-187.   doi: 10.3760/cma.j.issn.2095-2848.2013.03.007
[40] 郭峰, 汪清, 倪泽称, 等.  18F-FDG PET-CT显像在肾癌原发灶及转移灶诊断中的价值[J]. 医学临床研究, 2010, 27(10): 1827-1829, 1833.   doi: 10.3969/j.issn.1671-7171.2010.10.009
Guo F, Wang Q, Ni ZC, et al.  Comparison Study of 18F-FDG PET-CT and Enhanced-CT in the Diagnosis of Primary Lesion and Metastatic Lesion of Renal Carcinoma[J]. J Clin Res, 2010, 27(10): 1827-1829, 1833.   doi: 10.3969/j.issn.1671-7171.2010.10.009
[41] 徐白萱, 姚树林, 关志伟, 等.  18F-FDG PET(PET/CT)肾癌显像特点分析[J]. 军医进修学院学报, 2010, 31(7): 640-642.
Xu BX, Yao SL, Guan ZW, et al.  Characteristics of 18F-FDG PET for space occupying renal cancer[J]. J Chin PLA Postgrad Med Sch, 2010, 31(7): 640-642.
[42] 朱艳芳, 谢新立, 于艳霞, 等.  18F-FDG PET/CT显像SUVmax对不同病理分型肾细胞癌的鉴别价值[J]. 郑州大学学报(医学版), 2018, 53(6): 807-811.   doi: 10.13705/j.issn.1671-6825.2018.04.086
Zhu YF, Xie XL, Yu YX, et al.  Clinical application value of different pathological classifications of renal cell carcinoma using the SUVmax of 18F-FDG PET/CT[J]. J Zhengzhou Univ (Med Sci), 2018, 53(6): 807-811.   doi: 10.13705/j.issn.1671-6825.2018.04.086
[43] Kayani I, Avril N, Bomanji J, et al.  Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer[J]. Clin Cancer Res, 2011, 17(18): 6021-6028.   doi: 10.1158/1078-0432.CCR-10-3309
[44] 程远, 王振光.  18F-FDG PET/CT全身显像辐射剂量估计及风险评价[J]. 中华核医学与分子影像杂志, 2017, 37(7): 430-433.   doi: 10.3760/cma.j.issn.2095-2848.2017.07.012
Cheng Y, Wang ZG.  Estimation of patient radiation dose and risk from whole body 18F-FDG PET/CT examination[J]. Chin J Nucl Med Mol Imaging, 2017, 37(7): 430-433.   doi: 10.3760/cma.j.issn.2095-2848.2017.07.012